Cargando…
The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease
Hippocampal changes are associated with increased age and cognitive decline due to mild cognitive impairment (MCI) and Alzheimer's disease (AD). These associations are often observed only in the later stages of decline. This study examined if hippocampal grading, a method measuring local morpho...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171554/ https://www.ncbi.nlm.nih.gov/pubmed/36939138 http://dx.doi.org/10.1002/hbm.26269 |
_version_ | 1785039443589070848 |
---|---|
author | Morrison, Cassandra Dadar, Mahsa Shafiee, Neda Collins, D. Louis |
author_facet | Morrison, Cassandra Dadar, Mahsa Shafiee, Neda Collins, D. Louis |
author_sort | Morrison, Cassandra |
collection | PubMed |
description | Hippocampal changes are associated with increased age and cognitive decline due to mild cognitive impairment (MCI) and Alzheimer's disease (AD). These associations are often observed only in the later stages of decline. This study examined if hippocampal grading, a method measuring local morphological similarity of the hippocampus to cognitively normal controls (NCs) and AD participants, is associated with cognition in NCs, subjective cognitive decline (SCD), early (eMCI), late (lMCI), and AD. A total of 1620 Alzheimer's Disease Neuroimaging Initiative participants were examined (495 NC, 262 eMCI, 545 lMCI, and 318 AD) because they had baseline MRIs and Alzheimer's disease Assessment Scale (ADAS‐13) and Clinical Dementia Rating—Sum of Boxes (CDR‐SB) scores. In a sub‐analysis, NCs with episodic memory scores (as measured by Rey Auditory Verbal Learning Test, RAVLT) were divided into those with subjective cognitive decline (SCD+; 103) and those without (SCD−; 390). Linear regressions evaluated the influence of hippocampal grading on cognition in preclinical and prodromal AD. Lower global cognition, as measured by increased ADAS‐13, was associated with hippocampal grading: NC (p < .001), eMCI (p < .05), lMCI (p < .05), and AD (p = .01). Lower global cognition as measured increased CDR‐SB was associated with hippocampal grading in lMCI (p < .05) and AD (p < .001). Lower RAVLT performance was associated with hippocampal grading in SCD− (p < .05) and SCD+ (p < .05). These findings suggest that hippocampal grading is associated with global cognition in NC, eMCI, lMCI, and AD. Early changes in episodic memory during pre‐clinical AD are associated with changes in hippocampal grading. Hippocampal grading may be sensitive to progressive changes early in the disease course. |
format | Online Article Text |
id | pubmed-10171554 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101715542023-05-11 The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease Morrison, Cassandra Dadar, Mahsa Shafiee, Neda Collins, D. Louis Hum Brain Mapp Research Articles Hippocampal changes are associated with increased age and cognitive decline due to mild cognitive impairment (MCI) and Alzheimer's disease (AD). These associations are often observed only in the later stages of decline. This study examined if hippocampal grading, a method measuring local morphological similarity of the hippocampus to cognitively normal controls (NCs) and AD participants, is associated with cognition in NCs, subjective cognitive decline (SCD), early (eMCI), late (lMCI), and AD. A total of 1620 Alzheimer's Disease Neuroimaging Initiative participants were examined (495 NC, 262 eMCI, 545 lMCI, and 318 AD) because they had baseline MRIs and Alzheimer's disease Assessment Scale (ADAS‐13) and Clinical Dementia Rating—Sum of Boxes (CDR‐SB) scores. In a sub‐analysis, NCs with episodic memory scores (as measured by Rey Auditory Verbal Learning Test, RAVLT) were divided into those with subjective cognitive decline (SCD+; 103) and those without (SCD−; 390). Linear regressions evaluated the influence of hippocampal grading on cognition in preclinical and prodromal AD. Lower global cognition, as measured by increased ADAS‐13, was associated with hippocampal grading: NC (p < .001), eMCI (p < .05), lMCI (p < .05), and AD (p = .01). Lower global cognition as measured increased CDR‐SB was associated with hippocampal grading in lMCI (p < .05) and AD (p < .001). Lower RAVLT performance was associated with hippocampal grading in SCD− (p < .05) and SCD+ (p < .05). These findings suggest that hippocampal grading is associated with global cognition in NC, eMCI, lMCI, and AD. Early changes in episodic memory during pre‐clinical AD are associated with changes in hippocampal grading. Hippocampal grading may be sensitive to progressive changes early in the disease course. John Wiley & Sons, Inc. 2023-03-20 /pmc/articles/PMC10171554/ /pubmed/36939138 http://dx.doi.org/10.1002/hbm.26269 Text en © 2023 The Authors. Human Brain Mapping published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Morrison, Cassandra Dadar, Mahsa Shafiee, Neda Collins, D. Louis The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease |
title | The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease |
title_full | The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease |
title_fullStr | The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease |
title_full_unstemmed | The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease |
title_short | The use of hippocampal grading as a biomarker for preclinical and prodromal Alzheimer's disease |
title_sort | use of hippocampal grading as a biomarker for preclinical and prodromal alzheimer's disease |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171554/ https://www.ncbi.nlm.nih.gov/pubmed/36939138 http://dx.doi.org/10.1002/hbm.26269 |
work_keys_str_mv | AT morrisoncassandra theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease AT dadarmahsa theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease AT shafieeneda theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease AT collinsdlouis theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease AT theuseofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease AT morrisoncassandra useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease AT dadarmahsa useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease AT shafieeneda useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease AT collinsdlouis useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease AT useofhippocampalgradingasabiomarkerforpreclinicalandprodromalalzheimersdisease |